Demand for its microarray-based prenatal testing services drove growth for molecular diagnostics firm Combimatrix, which today reported a 6 percent year-over year-increase in first-quarter revenues. The company said that its total revenues for the second quarter and first six months of 2012 increased to $1.3 million and $2.6 million, respectively — up 6 percent and 19 percent from the second quarter and first six months of 2011.
"Our expanding test menu and ability to gain the samples earlier in the testing process has allowed us to gain market share in the prenatal segment," Judd Jessup, CombiMatrix President and CEO, says in a statement. He adds that his firm "recently signed a contract with a large prenatal customer that expects to begin shipping samples immediately and anticipates an ongoing quantity of samples that alone could increase our prenatal run rate by 20 to 50 percent in the coming year."
The Sample's sister publication GenomeWeb Daily News has more.